Home -> Law Blog Directory -> Personal Injury Law Blogs -> Des Moines Personal Injury Lawyer

Personal Injury Law

: Des Moines Personal Injury Lawyer

ISU research and H1N1, Are pigs luckier than are humans?

By Steve Lombardi

ISU research shows, H1N1 Virus Vaccine could have been readily available within 2 months of first case

Traditional methods can make a human vaccine in 5 to six months and for swine, 11 to 12 months. Aphavax, a North Carolina company developed a technique for more quickly developing vaccines for humans. Harrisvaccines, Inc. of the ISU Research Park is a start-up company has adapted the process for pigs. The technique is called RNA Backbone and using an electrical current uses electro-poration to combine the RNA Backbone material with genetic information from active flu virus.

What does RNA do in cells?

RNA serves a multitude of roles in living cells. These include: serving as a temporary copy of genes that is used as a template for protein synthesis (mRNA), functioning as adaptor molecules that decode the genetic code (tRNA) and catalyzing the synthesis of proteins (rRNA). There is much evidence implicating RNA structure in biological regulation and catalysis. Interestingly, RNA is the only biological polymer that serves as both a catalyst (like proteins) and as information storage (like DNA). For this reason, it has be postulated RNA, or an RNA-like molecule, was the basis of life early in evolution.

Further information can be obtained from the ISU New Service, Annette Hacker, director. 515-294-3720.

BELLS OF IOWA STATE UNIVERSITY, 1963 - Stanton Carillon at Iowa State University

http://www.youtube.com/watch?v=Wl0ov2m28yc

Harrisvaccines, Inc. is located at 2325 N LOOP DR, Ames, Iowa 50010

AlphaVax describes itself as:

AlphaVax is developing a novel vaccine technology with broad applications against infectious disease, cancer and biodefense threats which has the potential to redefine vaccines and the role they play in medicine. The vaccine market is primed for dramatic growth, and the AlphaVax vaccine technology will play a key role in an expanding industry expected to reach $20 billion by 2015.

AlphaVax uses a specialized viral vector system to make alphavirus replicon vaccines called alphavaccines, which have shown excellent protection in multiple models for infectious disease and cancer. Since 1998, the company has raised more than $154 million, with ~75% coming from corporate partner and grant funding. This support has enabled us to advance the alphavaccine platform system from the academic laboratory to multiple human clinical trials, establishing the technical, regulatory, and manufacturing foundation for commercializing alphavaccines. AlphaVax is the first company to advance an alphavirus-vectored vaccine to the clinical stage of development.

The AlphaVax in-house product pipeline includes products for Herpes Simplex virus (HSV) and respiratory diseases in the elderly and young, including influenza and Respiratory Syncytial Virus (RSV). Through partnered programs with Novartis Vaccines and Diagnostics and Progenics Pharmaceuticals, cytomegalovirus (CMV) and prostate cancer vaccines respectively based on the alphavaccine platform are being developed. In collaboration with government and university researchers, AlphaVax leads or participates in grant-funded programs to develop HIV, colon and breast cancer, and several biodefense vaccines.

Clinical data from the first alphavaccine human trials have established excellent safety and immunological activity in man. These immune responses are characterized as robust and balanced antibody (B-cell) and cellular (T-cell) immune responses, confirming the promising data that has been obtained in over a decade of intensive pre-clinical work with this vector platform.

We employ a staff of ~78 who are located in 3 facilities. The Company headquarters, located in Research Triangle Park (RTP), North Carolina is a state-of-the-art, 30,000-square-foot research facility that includes our Discovery and Research functions. A second facility also located in RTP at Meridian Parkway

houses a 10,000-square-foot Development facility. We also lease and operate a GMP vaccine manufacturing facility in Lenoir, North Carolina that supplies internal and partner phase I and Phase II clinical trial material.

MRNA VIDEO

http://www.youtube.com/watch?v=Lq5tiEW-aOY

http://www.youtube.com/watch?v=xzi_uRY90R8

http://www.youtube.com/watch?v=0248WyghCjc

http://www.youtube.com/watch?v=Fa4skYBJHoI

Originally posted at InjuryBoard by Steve Lombardi

Full post as published by Des Moines Personal Injury Lawyer on May 09, 2009 (boomark / email).